Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Assets: 2020-2025

Historic Assets for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $1.1 billion.

  • Apellis Pharmaceuticals' Assets rose 17.39% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 17.39%. This contributed to the annual value of $885.1 million for FY2024, which is 12.21% up from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Assets stood at $1.1 billion for Q3 2025, which was up 28.89% from $821.4 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' 5-year Assets high stood at $1.1 billion for Q1 2022, and its period low was $525.7 million during Q3 2021.
  • Moreover, its 3-year median value for Assets was $885.1 million (2024), whereas its average is $882.9 million.
  • Per our database at Business Quant, Apellis Pharmaceuticals' Assets plummeted by 31.58% in 2021 and then skyrocketed by 66.05% in 2022.
  • Over the past 5 years, Apellis Pharmaceuticals' Assets (Quarterly) stood at $881.8 million in 2021, then decreased by 13.78% to $760.2 million in 2022, then increased by 3.75% to $788.7 million in 2023, then increased by 12.21% to $885.1 million in 2024, then climbed by 17.39% to $1.1 billion in 2025.
  • Its Assets stands at $1.1 billion for Q3 2025, versus $821.4 million for Q2 2025 and $807.3 million for Q1 2025.